News and Announcements
Multi BD Ahead of Schedule for Second Projects with an Estimated Value of ~$79.9M
- Published July 14, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Multi BD is ahead of plan building a national network of Premium Medical Super Centres now having secured projects 1, 2 and 3 with an estimated end value of ~$79.9M.
Peter Terrill Co Executive Director said “We are ahead of plan securing 3 medical super centre projects with an ~$56M cost base and an end value target of ~$79.9M.
Negotiations with Tier 1 tenants for Pharmacy, Dental, Pathology and Allied Health are underway and General Practice will be secured through our Vita brand subsidiary operator.
We are also rapidly advancing discussions with capital partners on the creation of a $20-100M facility at which point we will close our 25% convertible note offer.
Bradley Birchall Co Executive Director said “Our rapid advance is down to solid operations and strategy backed by the new appointment of a very experienced team including;
- Richard Altrieth – Multi BD Director
- Antony Belcher – Property Director
- Bobby Cevetkovik – Acquisition Manager
Bradley went on to say “Given Generation Healthcare REIT was recently acquired for $2.30 a share valuing the deal at over $500+M on an asset base of ~$620M clearly demonstrates the undersupply of premium Healthcare assets and market demand. We are leading the charge with our integrated approach to development, management and operations in Healthcare and look forward to a successful 2017/18.
Various investor options are open but will be closed shortly, please contact us for further information.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
